^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MIR16 (MicroRNA 16)

    i
    Other names: MIR16, MicroRNA 16, MIR-16
    10d
    Circulating microRNAs as Biomarkers of Brain Metastases in Lung Cancer: A Pilot Study. (PubMed, J Clin Med)
    Notable differences in miRNA expression profiles were revealed for the patients with brain metastases from lung cancer, suggesting the role of the selected miRNAs in cancer metastasis to the CNS. However, while our analysis provides exploratory insights, the findings should be interpreted with caution and require validation in larger, independent cohorts before any clinical or translational implications can be established.
    Journal
    |
    MIR139 (MicroRNA 139) • MIR16 (MicroRNA 16) • MIR210 (MicroRNA 210) • MIR223 (MicroRNA 223) • MIR363 (MicroRNA 363) • MIR409 (MicroRNA 409) • MIR485 (MicroRNA 485) • MIR194 (MicroRNA 194) • MIR22 (MicroRNA 22) • MIR326 (MicroRNA 326)
    10d
    Liquid Biopsy Analysis of the EV-Associated Micro-RNA Signature in Vulvar Carcinoma May Benefit Disease Diagnosis and Prognosis. (PubMed, Cancers (Basel))
    Multivariate Cox regression showed that a model of downregulated miR-16-5p and upregulated miR-451a was significantly associated with poorer survival (p = 0.023). This study indicates the future potential of exomiRs as diagnostic and prognostic liquid biopsy markers for vulvar cancer.
    Journal • Liquid biopsy
    |
    MIR143 (MicroRNA 143) • MIR16 (MicroRNA 16) • MIR223 (MicroRNA 223) • MIR451A (MicroRNA 451a)
    13d
    Gene Expression Profiling to Unveil Novel Biomarkers for Early Diagnosis and Therapies for Breast Cancer. (PubMed, Curr Top Med Chem)
    The stability of the top three receptor-ligand complexes was validated through molecular dynamics simulations. Therefore, our findings could be a valuable resource for researchers and medical professionals, aiding in BC diagnosis and treatment.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CAV1 (Caveolin 1) • MIR155 (MicroRNA 155) • CD34 (CD34 molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD36 (thrombospondin receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    |
    Lynparza (olaparib) • lapatinib • Verzenio (abemaciclib) • Tukysa (tucatinib)
    21d
    Exploring CSF microRNA signatures as diagnostic biomarkers in adult-type diffuse gliomas. (PubMed, Noncoding RNA Res)
    Ingenuity Pathway Analysis (IPA) revealed that miR-16-5p and other miRNAs with seed AGCAGCA formed the largest interaction network in GBM, while disease enrichment analysis using Database for Annotation, Visualization, and Integrated Discovery (DAVID) confirmed that the 1000 predicted mRNA targets of DE-miRNAs in GBM were disease relevant. Collectively, these findings identify a robust panel of CSF-derived miRNAs capable of distinguishing IDH-mutant gliomas, GBM, and non-tumor states, supporting the potential of EV-miRNAs as minimally invasive biomarkers for the molecular characterization of diffuse gliomas.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • MIR21 (MicroRNA 21) • MIR142 (MicroRNA 142) • MIR16 (MicroRNA 16) • MIR19B1 (MicroRNA 19b-1) • MIR27B (MicroRNA 27b) • MIR99A (MicroRNA 99a) • MIR150 (MicroRNA 150) • MIR195 (MicroRNA 195) • MIR26A1 (MicroRNA 26a-1) • MIR30A (MicroRNA 30a) • MIR30E (MicroRNA 30e)
    |
    IDH wild-type
    26d
    Mechanisms of Chemoresistance in Malignant Pleural Mesothelioma: The Regulatory Role of miRNAs. (PubMed, Arch Med Res)
    EMT has been linked to the acquisition of a chemoresistant phenotype; moreover, the release of miRNAs into circulating exosomes from patients with MPM could also impact the resistance to conventional treatments. This review aims to summarize the current knowledge on the role of miRNAs in MPM and their relationship with chemoresistance, as well as to establish new knowledge to support the development of improved treatment for patients with MPM.
    Review • Journal
    |
    MIR16 (MicroRNA 16) • MIR15 (MicroRNA 15)
    26d
    Non-Coding RNA Biomarkers in Prostate Cancer: Evidence Mapping and In Silico Characterization. (PubMed, Life (Basel))
    Enrichment analysis showed strong overrepresentation of metabolic process-related GO terms and cancer-associated KEGG pathways. These findings refine the list of promising ncRNA biomarkers and highlight candidates for future clinical validation.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6) • MIR16 (MicroRNA 16) • MIR20A (MicroRNA 20a) • TBL1XR1 (TBL1X Receptor 1) • ACVR2B (Activin A Receptor Type 2B)
    26d
    Optical Genome Mapping Enhances Structural Variant Detection and Refines Risk Stratification in Chronic Lymphocytic Leukemia. (PubMed, Genes (Basel))
    Combining OGM and NGS analysis refined risk stratification beyond standard FISH panels and supports more precise, individualized management strategies in CLL. Prospective studies are warranted to evaluate the clinical utility of OGM-guided genomic profiling in contemporary treatment paradigms.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • IGH (Immunoglobulin Heavy Locus) • BIRC3 (Baculoviral IAP repeat containing 3) • BCL3 (BCL3 Transcription Coactivator) • MIR16 (MicroRNA 16) • MIR15A (MicroRNA 15a) • MIR16-1 (MicroRNA 16-1)
    |
    Chr del(11q) • IGH mutation • RB1 deletion
    26d
    Liquid Biopsy in Clear Cell Renal Cell Carcinoma: Diagnostic Potential of Urinary miRNAs. (PubMed, Cancers (Basel))
    These findings support urinary miRNAs as promising, minimally invasive biomarkers for ccRCC diagnosis and postoperative monitoring.
    Journal • Liquid biopsy
    |
    MIR16 (MicroRNA 16) • MIR210 (MicroRNA 210) • MIR15A (MicroRNA 15a) • MIR15B (MicroRNA 15b) • MIRLET7B (MicroRNA Let-7b)
    1m
    Circulating microRNAs Expression as Prognosis Biomarker of Cholangiocarcinoma. (PubMed, Asian Pac J Cancer Prev)
    These findings indicate that a panel of circulating miRNAs may serve as a useful tool for the diagnosis and prognosis of intrahepatic cholangiocarcinoma, warranting further validation in larger cohorts. Additionally, the accuracy of diagnostic tests may be improved by increasing the sample size and including diverse clinical subgroups to enhance the robustness and generalizability of the results.
    Journal
    |
    MIR16 (MicroRNA 16) • MIR223 (MicroRNA 223) • MIR23A (MicroRNA 23a) • MIR451A (MicroRNA 451a)
    1m
    Regulation of ferroptosis in colorectal cancer through therapeutic modulation and miRNA targeting. (PubMed, Biochem Biophys Rep)
    Interestingly, we also found that medications such as prasterone, tazemetostat, isoxyl, gemcitabine, ponsegromab, scx-2023, and nicotinamide could potentially be used in combination with the identified miRNAs to target ferroptosis in CRC. To further validate the stability and reliability of the predicted protein-ligand interactions, molecular dynamics (MD) simulations and MM-PBSA analyses were performed on selected top-ranking complexes, which confirmed their stable and favorable binding and supported the robustness of our docking results. These findings suggest that targeting these miRNAs and their associated genes, along with using the identified drugs, could be a promising strategy for CRC treatment, leveraging the potential of ferroptosis-inducing therapies.
    Journal • PARP Biomarker
    |
    PARP1 (Poly(ADP-Ribose) Polymerase 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • SLC7A11 (Solute Carrier Family 7 Member 11) • MIR16 (MicroRNA 16) • MIR15A (MicroRNA 15a) • MIR423 (MicroRNA 423) • MIR93 (MicroRNA 93)
    |
    gemcitabine • Tazverik (tazemetostat) • ponsegromab (PF-06946860)
    1m
    Differentially Expressed Genes Associated with the Development of Cervical Cancer. (PubMed, Int J Mol Sci)
    The publicly available microarray datasets, including GSE39001, GSE9750, GSE7803, GSE6791, GSE63514, and GSE52903 in combination with bioinformatics database predictions, were used to identify differential expression genes, potential biomarkers, and therapeutic targets for cervical cancer; additionally, we undertook bioinformatic analysis to determine gene ontology and possible miRNA targets related to our DEGs...Interestingly, hub proteins KIF4A, NUSAP1, BUB1B, CEP55, DLGAP5, NCAPG, CDK1, MELK, KIF11, and KIF20A were found to be potentially regulated by several miRNAs, including miR-107, miR-124-3p, miR-147a, miR-16-5p, miR-34a-5p, miR-34c-5p, miR-126-3p, miR-10b-5p, miR-23b-3p, miR-200b-3p, miR-138-5p, miR-203a-3p, miR-214-3p, and let-7b-5p. The relationship between these genes highlights their potential as candidate biomarkers for further research in treatment, diagnosis, and prognosis.
    Journal
    |
    TP53 (Tumor protein P53) • TOP2A (DNA topoisomerase 2-alpha) • RAD51 (RAD51 Homolog A) • MIR200B (MicroRNA 200b) • MIR34A (MicroRNA 34a-5p) • RAD51AP1 (RAD51 Associated Protein 1) • NUSAP1 (Nucleolar and Spindle Associated Protein 1) • ELF3 (E74 Like ETS Transcription Factor 3) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR126 (MicroRNA 126) • MIR16 (MicroRNA 16) • MIR23b (MicroRNA 23b) • NCAPG (Non-SMC Condensin I Complex Subunit G) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CEP55 (Centrosomal Protein 55) • CXCL14 (C-X-C Motif Chemokine Ligand 14) • E2F1 (E2F transcription factor 1) • KIF20A (Kinesin Family Member 20A) • KIF4A (Kinesin Family Member 4A) • MCM2 (Minichromosome maintenance complex component 2) • MCM5 (Minichromosome Maintenance Complex Component 5) • MIR10B (MicroRNA 10b) • MIR138 (MicroRNA 138) • MIR203A (MicroRNA 203a) • MIR214 (MicroRNA 214) • MIRLET7B (MicroRNA Let-7b) • RELA (RELA Proto-Oncogene) • RFC4 (Replication Factor C Subunit 4) • MIR124-3 (MicroRNA 124-3)
    2ms
    Differential Expression of Key Oncogenic and Tumor Suppressor MicroRNAs Induced by Andrographolide in Androgen-Independent PC3 and Androgen-Dependent LNCaP Prostate Cancer Cells. (PubMed, Genes (Basel))
    Although HEK-293 cytotoxicity and previously reported nephrotoxic effects warrant caution, these results support the potential of andrographolide as an adjuvant phytochemical capable of modulating clinically relevant miRNAs in prostate cancer. Future studies investigating optimized delivery systems and validating direct miRNA targets may help advance andrographolide toward safer and more targeted therapeutic applications.
    Journal
    |
    MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR200A (MicroRNA 200a) • MIR221 (MicroRNA 221) • MIR16 (MicroRNA 16)